Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-022288
Filing Date
2025-08-19
Accepted
2025-08-19 16:10:24
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11455
2 JOINT FILING AGREEMENT ex-99-08192025_080822.htm EX-99.1 2342
  Complete submission text file 0001415889-25-022288.txt   15440
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Subject) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93402 | Film No.: 251231882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 251 LITTLE FALLS DRIVE WILMINGTON DE 19808
Business Address 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 302-636-5401
Explore Investments LLC/DE (Filed by) CIK: 0002082302 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G